Agenus(US:AGEN) Businesswire·2024-03-06 12:30Core Insights - Agenus Inc. announced the presentation of preclinical data for BMS-986442 (AGEN1777) at the AACR Meeting scheduled for April 5-10, 2024, in San Diego, CA [1][4] Group 1: Product Development - BMS-986442 demonstrated superior immune activation in non-clinical assays both as a monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies [2] - This bispecific antibody targets two critical immune checkpoint receptors, TIGIT and CD96, utilizing Agenus' proprietary Fc-engineering platform to enhance its mechanisms of action beyond conventional anti-TIGIT therapies [2][3] - The bispecific antibody is being developed in partnership with Bristol Myers Squibb and is currently under investigation for treating multiple solid tumors in combination with nivolumab and/or chemotherapy [5] Group 2: Presentation Details - The abstract titled "BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models" will be presented by Dhan Chand on April 8, 2024, from 2:30 p.m. to 4:30 p.m. PST [4]